ULTRASOUND CONTRAST AGENTS FOR DETECTION OF LIVER TUMORS

用于检测肝脏肿瘤的超声造影剂

• 批准号: 3187492
• 负责人: KEVIN J PARKER
• 金额: $ 15.83万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-04-01 至 1991-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3187492
• 关键词: clinical biomedical equipment; image enhancement; laboratory mouse; laboratory rabbit; laboratory rat; liver neoplasms; particle; ultrasonography

The objective of this proposal is to develop and evaluate several particulate ultrasonic contrast agents which selectively accumulate in normal liver parenchyma but not in most tumors. Ultrasound is frequently employed for liver evaluation in both staging and followup of therapy because of its availability, low cost, and easy patient acceptance. However, neoplastic liver lesions have variable ultrasonographic features which can hinder detection by this modality. Even modest improvements in sensitivity using contrast enhancement would enhance the utility of ultrasound for primary screening and for followup of already demonstrated liver metastases. We propose to thoroughly evaluate iodipamide ethyl ester (IDE) particulate suspensions to develop models for ultrasound-particle and ultrasound-particle-tissue interactions. Preliminary experiments using IDE particles suspended in agar demonstrated that IDE increased ultrasonic backscatter and attenuation coefficients with increased particle diameter and concentration. B-scan images of rabbit livers (in vivo) and rat livers (ex vivo) containing IDE particles showed greater contrast enhancement compared to control livers than was anticipated from studies of agar. The additional mechanisms which act in liver require further investigation. Additional studies of other particulate agents covering a range of mechanical properties (compressibility and density) should indicate the desirable chemical-mechanical properties for optimization of ultrasound contrast enhancement. New particulate ultrasonic contrast agents will be produced using technology already developed for IDE. Ultrasonic evaluation of these new agents, using instrumentation developed at this institution as well as commercial imaging equipment, will start with simple agar suspensions and proceed to more complex experiments involving mice for safety evaluation and normal rats, normal rabbits, and rabbits with liver tumor implants for efficacy evaluation. Screening of each new contrast agent will terminate with the least complex study which demonstrates the agent is not superior to IDE. The investigators have experience with all of the methodology proposed in this application. The proposed studies, combining a unique technology for particulate suspension formulation and unique instrumentation for precise measurement of ultrasonic properties of normal and treated tissues should produce quantitative understanding of ultrasound-particle-tissue interactions and, possibly, a clinically useful ultrasound contrast agent.

该提议的目的是开发和评估几个 颗粒超声造影剂，有选择地 在正常的肝实质中积聚，但在大多数肿瘤中均积聚。 超声经常用于两者的肝脏评估 由于其可用性而进行的分期和随访 成本，容易患者接受。 但是，肿瘤肝 病变具有可变的超声特征，可以阻碍 通过这种方式检测。 甚至适度的改进 使用对比度增强的灵敏度将增强实用性 超声检查的主要筛选和随访 证明肝转移。 我们建议彻底评估碘氨基胺乙酯（IDE） 颗粒悬浮液以开发超声粒子的模型 和超声粒子组织相互作用。 初步的 使用悬浮在琼脂中的IDE颗粒的实验证明了 IDE增加了超声波反向散射和衰减 颗粒直径和浓度增加的系数。 兔肝（体内）和大鼠肝（Ex Vivo）的B扫描图像 包含IDE颗粒显示出更大的对比度增强 与对照肝脏相比 琼脂。 在肝脏中起作用的其他机制需要 进一步调查。 其他颗粒物的其他研究 涵盖一系列机械性能的代理（可压缩性 密度）应指示理想的化学机械机械 优化超声对比度增强的特性。 使用新的颗粒超声对比剂将使用 已经为IDE开发的技术。 超声评估 这些新代理，使用在此开发的仪器 机构以及商业成像设备将开始 使用简单的琼脂悬浮液，然后进行更复杂的 涉及小鼠安全评估和正常大鼠的实验， 正常兔子和肝肿瘤植入物的兔子有效性 评估。 每个新对比代理的筛查将终止 通过最不复杂的研究，证明代理不是 优于IDE。 调查人员有所有的经验 在本应用程序中提出的方法。 拟议的研究结合了独特的技术 颗粒悬架配方和独特的仪器 精确测量正常的超声特性 处理的组织应对 超声粒子组织的相互作用，可能是临床上的 有用的超声对比剂。